ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2301

Gout and Subsequent Risk of Incident Erectile Dysfunction: A Population-Based Cohort Study from the United Kingdom

Alyshah Abdul Sultan1, Christian Mallen2, Richard Hayward1, Sara Muller2, Rebecca Whittle3, Matthew Hotston4 and Edward Roddy2, 1Research Institute of Primary Care & Health Sciences, Keele University, Keele, United Kingdom, 2Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, 3Research Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, United Kingdom, 4Urology, Royal Cornwall Hospital, Truro, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Comorbidity and gout

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most prevalent inflammatory arthritis, affecting 2.4% of adults in the UK. Recently, a link has been suggested between gout and erectile dysfunction (ED), however studies quantifying ED reporting by gout patients are lacking. The aim of this study was to determine the population level absolute and relative rates of ED reporting by patients with gout over a decade in England. 

Methods: Utilising data from one of the largest English primary care consultation databases (Clinical Practice Research Datalink), we identified 9,653 men with incident gout and matched them to 38,218 controls (ratio 1:4) by age and practice.  Absolute and relative rate of incident ED was calculated using Cox regression models. Absolute rates within specific time periods before and after gout diagnosis were compared to controls using Poisson regression models.

 

Results: Overall, the absolute rate of ED post-gout diagnosis was 193 (95% Confidence interval (CI): 184-202) per 10,000 person-years. This corresponded to a 31% (Hazard Ratio (HR) = 1.31 95%CI: 1.24-1.40) increased relative risk and 0.6% excess absolute risk compared to those without gout (Table 1). Among those prescribed urate-lowering therapy, the risk of ED was similar for cases and controls (HR=1.10 95CI: 1.01-1.19). Compared to controls, the risk of ED was also high in the year before gout diagnosis (incidence rate ratio= 1.63 95%CI 1.27-2.08). Our relative risk estimates remained broadly similar when we restricted our analyses to those with ED treated with medication.

Conclusion: We have shown a statistically significant increased risk of ED among men with gout, however, the absolute risk difference is small indicating limited influence of disease on ED. Clinicians should be aware that higher reporting of ED before gout diagnosis suggests a possible influence of hyperuricemia on arterial vasculature warranting further investigations. Overall our finding are reassuring to patients and clinicians.

    Table 1: Absolute and relative rate of Erectile Dysfunction after gout diagnosis

Variable Cases Rate1 (95% CI) Controls Rate (95% CI) Hazard Ratio2 (95% CI) Absolute risk difference1
         
Overall Erectile Dysfunction        
All ages 192.8 (184.0-202.1) 136.2 (132.1-140.4) 1.31 (1.24-1.40) 56.6
≤34 61.4 (45.4-127.4) 34.6 (27.3-43.9) 1.20 (0.79-1.83) 26.8
35 – 44  112.4 (99.5-127.4) 76.2 (70.1-82.8) 1.18 (1.01-1.39) 36.4
45 – 54 211.7 (196.1-228.6) 146.0 (138.6-153.5) 1.28 (1.16-1.41) 65.7
55 – 64 262.8 (245.1-281.4) 186.3 (178.3-194.8) 1.37 (1.25-1.49) 76.5
         
Medication treated Erectile Dysfunction        
All ages 80.2 (77.1-83.5) 113.7 (107.0-120.9) 1.36 (1.26-1.47) 33.5
≤34 16.3 (11.5-23.0) 33.6 (22.4-50.9) 1.24 (0.67-2.29) 17.3
35 – 44  45.7 (41.1-51.0) 62.4 (52.8-73.6) 1.11 (0.89-1.37) 16.6
45 – 54 87.1 (81.6-92.9) 126.8 (114.8-140.0) 1.30 (1.15-1.47) 39.7
55 – 64 108.8 (102.7-115.3) 156.7 (143.2-171.5) 1.46 (1.30-1.64) 47.9

1Per 10,000 person-years 2Adjusted for smoking status, Alcohol consumption, Body Mass Index, age, Ischemic heart disease, chronic diseases, hypertension, diabetes and depression.  


Disclosure: A. Abdul Sultan, None; C. Mallen, None; R. Hayward, None; S. Muller, None; R. Whittle, None; M. Hotston, None; E. Roddy, None.

To cite this abstract in AMA style:

Abdul Sultan A, Mallen C, Hayward R, Muller S, Whittle R, Hotston M, Roddy E. Gout and Subsequent Risk of Incident Erectile Dysfunction: A Population-Based Cohort Study from the United Kingdom [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/gout-and-subsequent-risk-of-incident-erectile-dysfunction-a-population-based-cohort-study-from-the-united-kingdom/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gout-and-subsequent-risk-of-incident-erectile-dysfunction-a-population-based-cohort-study-from-the-united-kingdom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology